Nerve growth factor and neural oncology

S. A. Vinores, J. R. Perez Polo

    Research output: Contribution to journalArticle

    18 Citations (Scopus)

    Abstract

    The precise role of the nerve growth factor protein (NGF) during the growth and development of the human nervous system is not determined. Although it appears to influence a number of neural functions, its mechanism of action is poorly understood. A number of researchers have proposed that NGF may be involved in several pathological conditions including cancer. It has been shown that NGF is secreted by certain sarcoma (23), neuroblastoma (113), and glioma (7, 102, 136) cell lines and can bind to neuroblastoma and metastatic melanoma cell lines (42). Neuroblastoma (136, 181) and pheochromocytoma (165) cells in vitro can be induced by NGF to differentiate toward a morphologicaly 'more benign' state and appropriate NGF treatment of rats can reduce the number of chemically induced gliomas and neurinomas (174, 178). NGF can also reduce the growth of intracerebrally inoculated anaplastic glioma cells (172). Anti-NGF treatment of rats (178) and mice (179) can alter the tumor distribution observed following ethylnitrosourea or benzo(a)pyrene treatment (10). In humans, it has been reported that serum levels of NGF are usually elevated in persons 'at risk' for neurofibromatosis (156). The precise nature of the NGF role is not known in these instances. Further understanding of the action of NGF could be of clinical importance.

    Original languageEnglish (US)
    Pages (from-to)81-100
    Number of pages20
    JournalJournal of Neuroscience Research
    Volume9
    Issue number1
    StatePublished - 1983

    Fingerprint

    Nerve Growth Factor
    Proteins
    Neuroblastoma
    Glioma
    Ethylnitrosourea
    Cell Line
    Neurofibromatoses
    Benzo(a)pyrene
    Neurilemmoma
    Pheochromocytoma
    Growth and Development
    Sarcoma
    Nervous System
    Melanoma
    Neoplasms
    Research Personnel

    ASJC Scopus subject areas

    • Neuroscience(all)

    Cite this

    Vinores, S. A., & Perez Polo, J. R. (1983). Nerve growth factor and neural oncology. Journal of Neuroscience Research, 9(1), 81-100.

    Nerve growth factor and neural oncology. / Vinores, S. A.; Perez Polo, J. R.

    In: Journal of Neuroscience Research, Vol. 9, No. 1, 1983, p. 81-100.

    Research output: Contribution to journalArticle

    Vinores, SA & Perez Polo, JR 1983, 'Nerve growth factor and neural oncology', Journal of Neuroscience Research, vol. 9, no. 1, pp. 81-100.
    Vinores SA, Perez Polo JR. Nerve growth factor and neural oncology. Journal of Neuroscience Research. 1983;9(1):81-100.
    Vinores, S. A. ; Perez Polo, J. R. / Nerve growth factor and neural oncology. In: Journal of Neuroscience Research. 1983 ; Vol. 9, No. 1. pp. 81-100.
    @article{2d8b598095e540bbb9c66af99fa96d07,
    title = "Nerve growth factor and neural oncology",
    abstract = "The precise role of the nerve growth factor protein (NGF) during the growth and development of the human nervous system is not determined. Although it appears to influence a number of neural functions, its mechanism of action is poorly understood. A number of researchers have proposed that NGF may be involved in several pathological conditions including cancer. It has been shown that NGF is secreted by certain sarcoma (23), neuroblastoma (113), and glioma (7, 102, 136) cell lines and can bind to neuroblastoma and metastatic melanoma cell lines (42). Neuroblastoma (136, 181) and pheochromocytoma (165) cells in vitro can be induced by NGF to differentiate toward a morphologicaly 'more benign' state and appropriate NGF treatment of rats can reduce the number of chemically induced gliomas and neurinomas (174, 178). NGF can also reduce the growth of intracerebrally inoculated anaplastic glioma cells (172). Anti-NGF treatment of rats (178) and mice (179) can alter the tumor distribution observed following ethylnitrosourea or benzo(a)pyrene treatment (10). In humans, it has been reported that serum levels of NGF are usually elevated in persons 'at risk' for neurofibromatosis (156). The precise nature of the NGF role is not known in these instances. Further understanding of the action of NGF could be of clinical importance.",
    author = "Vinores, {S. A.} and {Perez Polo}, {J. R.}",
    year = "1983",
    language = "English (US)",
    volume = "9",
    pages = "81--100",
    journal = "Journal of Neuroscience Research",
    issn = "0360-4012",
    publisher = "Wiley-Liss Inc.",
    number = "1",

    }

    TY - JOUR

    T1 - Nerve growth factor and neural oncology

    AU - Vinores, S. A.

    AU - Perez Polo, J. R.

    PY - 1983

    Y1 - 1983

    N2 - The precise role of the nerve growth factor protein (NGF) during the growth and development of the human nervous system is not determined. Although it appears to influence a number of neural functions, its mechanism of action is poorly understood. A number of researchers have proposed that NGF may be involved in several pathological conditions including cancer. It has been shown that NGF is secreted by certain sarcoma (23), neuroblastoma (113), and glioma (7, 102, 136) cell lines and can bind to neuroblastoma and metastatic melanoma cell lines (42). Neuroblastoma (136, 181) and pheochromocytoma (165) cells in vitro can be induced by NGF to differentiate toward a morphologicaly 'more benign' state and appropriate NGF treatment of rats can reduce the number of chemically induced gliomas and neurinomas (174, 178). NGF can also reduce the growth of intracerebrally inoculated anaplastic glioma cells (172). Anti-NGF treatment of rats (178) and mice (179) can alter the tumor distribution observed following ethylnitrosourea or benzo(a)pyrene treatment (10). In humans, it has been reported that serum levels of NGF are usually elevated in persons 'at risk' for neurofibromatosis (156). The precise nature of the NGF role is not known in these instances. Further understanding of the action of NGF could be of clinical importance.

    AB - The precise role of the nerve growth factor protein (NGF) during the growth and development of the human nervous system is not determined. Although it appears to influence a number of neural functions, its mechanism of action is poorly understood. A number of researchers have proposed that NGF may be involved in several pathological conditions including cancer. It has been shown that NGF is secreted by certain sarcoma (23), neuroblastoma (113), and glioma (7, 102, 136) cell lines and can bind to neuroblastoma and metastatic melanoma cell lines (42). Neuroblastoma (136, 181) and pheochromocytoma (165) cells in vitro can be induced by NGF to differentiate toward a morphologicaly 'more benign' state and appropriate NGF treatment of rats can reduce the number of chemically induced gliomas and neurinomas (174, 178). NGF can also reduce the growth of intracerebrally inoculated anaplastic glioma cells (172). Anti-NGF treatment of rats (178) and mice (179) can alter the tumor distribution observed following ethylnitrosourea or benzo(a)pyrene treatment (10). In humans, it has been reported that serum levels of NGF are usually elevated in persons 'at risk' for neurofibromatosis (156). The precise nature of the NGF role is not known in these instances. Further understanding of the action of NGF could be of clinical importance.

    UR - http://www.scopus.com/inward/record.url?scp=0020663095&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0020663095&partnerID=8YFLogxK

    M3 - Article

    C2 - 6300414

    AN - SCOPUS:0020663095

    VL - 9

    SP - 81

    EP - 100

    JO - Journal of Neuroscience Research

    JF - Journal of Neuroscience Research

    SN - 0360-4012

    IS - 1

    ER -